Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nal-IRI + fluorouracil + sodium levofolinate
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of nanoliposomal irinotecan (nal-IRI), fluorouracil (5-FU), and sodium levofolinate. Nal-IRI is a liposomal formulation of irinotecan, a topoisomerase I inhibitor that interferes with DNA replication in cancer cells. Fluorouracil is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and function. Sodium levofolinate (the disodium salt of the active stereoisomer of folinic acid) enhances the binding of fluorouracil to thymidylate synthase, increasing its cytotoxic effect. This combination has been approved for use in advanced pancreatic cancer after progression on gemcitabine-based therapy and is also used off-label or in clinical trials for other gastrointestinal cancers[2][4][8]. The regimen improves survival compared to monotherapy with either agent alone and offers manageable toxicity[4][2]. Sodium levofolinate provides advantages over calcium levofolinate due to improved solubility, allowing co-administration with 5-FU in a single infusion pump[1][6].
- Brand names
- Onivyde (for nal-IRI)
- Other names
- nanoliposomal irinotecan + 5-fluorouracil + sodium levofolinateliposomal irinotecan + 5-FU + Na-levofolinatenal-IRI + 5-FU/Levo-LV
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on nal-IRI + fluorouracil + sodium levofolinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nal-IRI + fluorouracil + sodium levofolinate.